Frenkel Ran
- SEC CIK
- 0001623108
No open-market purchases or sales filed in the past year.
Current role at each company
- KPTI Karyopharm Therapeutics Inc.EVP, Chief Dev. Officeras of Mar 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Frenkel Ran as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −1.66K | $10.24 | −$17.0K | −1.0%168.3K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −2.93K | $12.12 | −$35.5K | −2.8%101.7K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −1.99K | $9.86 | −$19.6K | −1.9%104.6K after |